R
5.23
-0.30 (-5.42%)
| Previous Close | 5.53 |
| Open | 5.56 |
| Volume | 33,784,582 |
| Avg. Volume (3M) | 26,527,687 |
| Market Cap | 2,283,148,800 |
| Price / Sales | 30.78 |
| Price / Book | 2.62 |
| 52 Weeks Range | |
| Earnings Date | 6 Nov 2025 |
| Operating Margin (TTM) | -1,297.85% |
| Diluted EPS (TTM) | -1.80 |
| Quarterly Revenue Growth (YOY) | 6.90% |
| Total Debt/Equity (MRQ) | 9.95% |
| Current Ratio (MRQ) | 4.11 |
| Operating Cash Flow (TTM) | -388.83 M |
| Levered Free Cash Flow (TTM) | -204.88 M |
| Return on Assets (TTM) | -38.51% |
| Return on Equity (TTM) | -86.10% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Recursion Pharmaceuticals, Inc. | Mixed | Bearish |
AIStockmoo Score
-1.2
| Analyst Consensus | 0.5 |
| Insider Activity | -1.5 |
| Price Volatility | -2.0 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | -0.5 |
| Average | -1.20 |
|
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 4.78% |
| % Held by Institutions | 69.39% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Kinnevik Ab (Publ) | 30 Jun 2025 | 13,434,171 |
| 52 Weeks Range | ||
| Median | 8.00 (52.96%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Needham | 11 Sep 2025 | 8.00 (52.96%) | Buy | 4.85 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| GIBSON CHRISTOPHER | - | 5.73 | -100,000 | -573,000 |
| Aggregate Net Quantity | -100,000 | |||
| Aggregate Net Value ($) | -573,000 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 5.73 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| GIBSON CHRISTOPHER | Officer | 23 Oct 2025 | 100,000 | - | - | |
| GIBSON CHRISTOPHER | Officer | 23 Oct 2025 | Automatic sell (-) | 100,000 | 5.73 | 573,000 |
| Date | Type | Details |
|---|---|---|
| 05 Nov 2025 | Announcement | Recursion Reports Third Quarter 2025 Financial Results and Provides Business Update |
| 05 Nov 2025 | Announcement | Recursion Announces CEO Transition Plan to Drive Next Phase of Growth |
| 04 Nov 2025 | Announcement | Recursion to Participate in Upcoming Investor Conferences |
| 28 Oct 2025 | Announcement | Recursion to Report Third Quarter 2025 Business Updates and Financial Results on November 5th |
| 27 Aug 2025 | Announcement | Recursion to Participate in Upcoming Investor Conferences |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |